{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:09:34Z","timestamp":1791551374211,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.ijantimicag.2005.06.001","type":"journal-article","created":{"date-parts":[[2005,7,21]],"date-time":"2005-07-21T16:40:07Z","timestamp":1121964007000},"page":"101-105","source":"Crossref","is-referenced-by-count":60,"title":["New approaches to the antibiotic treatment of brucellosis"],"prefix":"10.1016","volume":"26","author":[{"given":"Georgios","family":"Pappas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Solera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Akritidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epameinondas","family":"Tsianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2005.06.001_bib1","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMra050570","article-title":"Brucellosis","volume":"352","author":"Pappas","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2310\/7060.2004.13551","article-title":"Brucellosis and international travel","volume":"11","author":"Memish","year":"2004","journal-title":"J Travel Med"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/315876","article-title":"Infectious disease morbidity in the US region bordering Mexico, 1990\u20131998","volume":"182","author":"Doyle","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib4","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1086\/313524","article-title":"Brucellar spondylitis: review of 35 cases and literature survey","volume":"29","author":"Solera","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0378-1135(02)00255-9","article-title":"Brucellosis vaccines: past, present and future","volume":"90","author":"Schurig","year":"2002","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib6","unstructured":"World Health Organization. Joint FAO\/WHO Expert Committee on Brucellosis. Sixth report. Technical Report Series 740. Geneva, Austria: WHO; 1986. p. 1\u2013132."},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib7","unstructured":"World Health Organization. Joint FAO\/WHO Expert Committee on Brucellosis. Fifth report. Technical Report Series 464. Geneva, Austria: WHO; 1971. p. 1\u201376."},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jama.1960.63020070004016","article-title":"Current status of therapy of brucellosis in human beings","volume":"172","author":"Spink","year":"1960","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/infdis\/136.4.482","article-title":"Rifampin in the treatment of experimental brucellosis in mice and guinea pigs","volume":"136","author":"Philippon","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1440-1843.2001.00344.x","article-title":"Progressive rise of Mycobacterium tuberculosis resistance to rifampicin and streptomycin in Riyadh, Saudi Arabia","volume":"6","author":"Al-Hajjaj","year":"2001","journal-title":"Respirology"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0378-1135(02)00214-6","article-title":"Brucella intracellular life: from invasion to intracellular replication","volume":"90","author":"Gorvel","year":"2002","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/713608012","article-title":"T cell immunity to brucellosis","volume":"29","author":"Yingst","year":"2003","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib13","doi-asserted-by":"crossref","unstructured":"Solera J, Beato JL, Martinez-Alfaro E, Segura JC, de Tomas E; Grupo de Estudio de Castilla la Mancha de Enfermedades Infecciosas Group. Azithromycin and gentamicin therapy for the treatment of humans with brucellosis. Clin Infect Dis 2001;32:506\u2013509.","DOI":"10.1086\/318503"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib14","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/clinids\/14.2.506","article-title":"Failure of ceftriaxone in the treatment of acute brucellosis","volume":"14","author":"Lang","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jac\/26.6.841","article-title":"Failure of prolonged treatment with ciprofloxacin in acute infections due to Brucella melitensis","volume":"26","author":"Lang","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib16","first-page":"3","article-title":"Ciprofloxacin in the treatment of patients with brucellosis","volume":"47","author":"Duisenova","year":"2002","journal-title":"Antibiot Khimioter"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib17","first-page":"39","article-title":"Effectiveness of pefloxacin in brucellosis","volume":"40","author":"Kurmanova","year":"1995","journal-title":"Antibiot Khimioter"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib18","first-page":"13","article-title":"Efficacy of some new antibiotics in treating experimental brucellosis","volume":"47","author":"Maletskaia","year":"2002","journal-title":"Antibiot Khimioter"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jac\/36.4.647","article-title":"Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice","volume":"36","author":"Domingo","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijantimicag.2004.11.006","article-title":"Tigecycline: clinical evidence and formulary positioning","volume":"25","author":"Nathwani","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jac\/dkh125","article-title":"Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA","volume":"53","author":"Bauer","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00003495-200464010-00005","article-title":"The glycylcyclines: a comparative review with the tetracyclines","volume":"64","author":"Zhanel","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0378-1135(02)00241-9","article-title":"Brucellosis in Mexico: current status and trends","volume":"90","author":"Luna-Martinez","year":"2002","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib24","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1086\/426024","article-title":"A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis","volume":"39","author":"Solera","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0163-4453(98)93342-4","article-title":"Multivariate model for predicting relapse in human brucellosis","volume":"36","author":"Solera","year":"1998","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib26","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/clinids\/20.5.1241","article-title":"Characteristics of and risk factors for relapse of brucellosis in humans","volume":"20","author":"Ariza","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijantimicag.2004.05.003","article-title":"Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen","volume":"24","author":"Pappas","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/clinids\/22.3.441","article-title":"Treatment of human brucellosis with netilmicin and doxycycline","volume":"22","author":"Solera","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/AAC.41.1.80","article-title":"Treatment of human brucellosis with doxycycline and gentamicin","volume":"41","author":"Solera","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib30","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/378125","article-title":"Brucellosis and the respiratory system","volume":"37","author":"Pappas","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib31","first-page":"564","article-title":"Comparison of the efficacy of two months of treatment with co-trimoxazole plus doxycycline vs. co-trimoxazole plus rifampin in brucellosis","volume":"134","author":"Roushan","year":"2004","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1179\/joc.2003.15.3.248","article-title":"Treatment of human brucellosis with rifampin plus minocycline","volume":"15","author":"Cascio","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib33","first-page":"202","article-title":"Effective treatments in the management of brucellosis","volume":"2","author":"Pappas","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib34","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1128\/AAC.38.12.2798","article-title":"Possible implications of doxycycline\u2013rifampin interaction for treatment of brucellosis","volume":"38","author":"Colmenero","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib35","first-page":"746","article-title":"Effects of rifampicin on the pharmacodynamics of doxycycline","volume":"35","author":"Garraffo","year":"1987","journal-title":"Pathol Biol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jac\/33.3.545","article-title":"Efficacy of combinations of doxycycline and rifampicin in the therapy of experimental mouse brucellosis","volume":"33","author":"Shasha","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.30.6.958","article-title":"Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis","volume":"30","author":"Ariza","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib38","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1128\/JCM.42.12.5439-5443.2004","article-title":"Genetic bases of the rifampin resistance phenotype in Brucella spp.","volume":"42","author":"Marianelli","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijantimicag.2003.09.024","article-title":"In vitro antimicrobial susceptibility of Brucella species","volume":"23","author":"Baykam","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib40","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/18.5.648","article-title":"Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin","volume":"18","author":"De Rautlin de la Roy","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib41","first-page":"60","article-title":"Co-trimoxazole resistant Brucella","volume":"47","author":"Bannatyne","year":"2001","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/jac\/25.2.302","article-title":"Development of ciprofloxacin resistance in Brucella melitensis","volume":"25","author":"al-Sibai","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archinte.159.2.167","article-title":"Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine","volume":"159","author":"Raoult","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000084020","article-title":"The effect of the doxycycline\u2013rifampicin and levamisole combination on lymphocyte subgroups and functions of phagocytic cells in patients with chronic brucellosis","volume":"51","author":"Dizer","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib45","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3109\/08923979409019745","article-title":"Immunotherapy in chronic brucellosis. Effect of levamisole and interferon; mechanisms of action and clinical value","volume":"16","author":"Printzis","year":"1994","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/205873929901200208","article-title":"Effect of bacterial extracts on the immunologic profile in chronic relapsing brucellosis patients","volume":"12","author":"Boura","year":"1999","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib47","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1172\/JCI102688","article-title":"The influence of cortisone and adrenocorticotrophic hormone on brucellosis. II. Adrenocorticotrophic hormone (ACTH) in acute and chronic human brucellosis","volume":"31","author":"Spink","year":"1952","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2005.06.001_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CMR.16.1.65-78.2003","article-title":"Molecular host\u2013pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans","volume":"16","author":"Ko","year":"2003","journal-title":"Clin Microbiol Rev"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905001639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T08:50:03Z","timestamp":1551948603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857905001639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0924857905001639"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2005.06.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}